[Urological cancers: ECCO/ESMO congress 2011].
In the Congress of European Cancer Organisation (ECCO)/European Society for Medical Oncology (ESMO), which took place in Stockholm between 23 and 27 September 2011, urological cancers were the subject of various oral presentations and posters. A selection of the more innovative researches, likely to change the patients' management was performed. In prostate cancer, abiraterone acetate should be indicated in patients previously treated with docetaxel and sipuleucel-T in patients with asymptomatic or minimally symptomatic castrate-resistant prostate cancer. Alpharadine should be indicated in patients with symptomatic bone metastases and denosumab in non-metastatic prostate cancer patients with a high risk of developing bone metastases. In metastatic renal clear cell carcinoma, the genetic polymorphisms are predictive for efficacy of anti-angiogenic agents. Targeting both vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) pathways is a very promising strategy. In urothelial cancer, two molecules are promising, the belinostat and the bortezomib. Other news on penile cancer and testicular seminoma are discussed.
Centre régional d'oncologie, hôpital Hassan II, département d'oncologie médicale, Agadir 80000, Maroc. ismailinabil@yahoo.fr
Nabil
N
Ismaili
Said
S
Afqir
Rhizlane
R
Belbaraka
Sanaa
S
Elmajjaoui
Noureddine
N
Benjaafar
Ali
A
Tahri
Hassan
H
Errihani
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D008495:Medical Oncology; D011719:Pyrazines / Q000627:therapeutic use; D012955:Societies, Medical; D013449:Sulfonamides / Q000627:therapeutic use; D013548:Sweden; D014571:Urologic Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D006877:Hydroxamic Acids; D011719:Pyrazines; D013449:Sulfonamides; D000069286:Bortezomib; C487081:belinostat